Gilead Sciences (GILD) Preferred Stock Liabilities (2012 - 2015)
Gilead Sciences' (GILD) quarterly Preferred Stock Liabilities came in at $2.0 million in Q4 2015, down 86.67% YoY from $15.0 million in Q4 2014, and down 50.0% on a QoQ basis from $4.0 million in Q3 2015.
Gilead Sciences (GILD) Preferred Stock Liabilities (2012 - 2015) Analysis & Trends
Gilead Sciences (GILD) has 4 years of Preferred Stock Liabilities data on file, last reported at $2.0 million in Q4 2015.
- Quarterly Preferred Stock Liabilities fell 86.67% year-over-year to $2.0 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $2.0 million (down 86.67% YoY) and the FY2015 annual result came in at $2.0 million, down 86.67% from the prior year.
- Preferred Stock Liabilities slipped to $2.0 million in Q4 2015, from $4.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $64.0 million in Q4 2013 to a low of $2.0 million in Q4 2015.
- A 4-year average of $21.9 million and a median of $13.0 million in 2014 frame the typical range for Preferred Stock Liabilities.
- Annual changes were most pronounced in 2013 — Preferred Stock Liabilities surged 795.48% — and 2015, when it sank 86.67%.
- Tracing GILD's Preferred Stock Liabilities over 4 years: stood at $7.1 million in 2012, then jumped by 795.48% to $64.0 million in 2013, then sank by 76.56% to $15.0 million in 2014, then slumped by 86.67% to $2.0 million in 2015.
- The last three Preferred Stock Liabilities figures came in at $2.0 million (Q4 2015), $4.0 million (Q3 2015), and $7.0 million (Q2 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 2.00 Mn |
| Sep 30, 2015 | 4.00 Mn |
| Jun 30, 2015 | 7.00 Mn |
| Mar 31, 2015 | 11.00 Mn |
| Dec 31, 2014 | 15.00 Mn |
| Sep 30, 2014 | 27.38 Mn |
| Jun 30, 2014 | 35.88 Mn |
| Mar 31, 2014 | 45.77 Mn |
| Dec 31, 2013 | 64.00 Mn |
| Dec 31, 2012 | 7.15 Mn |